Bluejay Diagnostics Q3 net loss $2.29M; Toray license cut to 7.5% royalty

Bluejay Diagnostics, Inc.

2023-Q3 EPS reported -$7.30 vs consensus -$1330.08 ▲ beat (+99.5%)

Net loss $2.29M ($2.08/share) for Q3 2023; nine-month loss $7.65M ($7.30/share).
Cash $5.08M as of Sep 30, 2023, down from $10.1M; expects funding into Q1 2024, needs more capital.
Renegotiated Toray license: royalty reduced from 15% to 7.5% for 10 years; 50% reduction after patent expiry.
Plans to submit FDA 510(k) for Symphony IL-6 in first half 2024 based on August 2023 feedback.
Also renegotiated supply agreement with Toray for cartridge component supply for clinical studies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Bluejay Diagnostics, Inc. reported the three and nine months ended September 30, 2023 results: net income $2.29 million and $7.65 million, EPS $2.08 and $7.30 per share.

Period: the three and nine months ended September 30, 2023
Net income: $2.29 million and $7.65 million
EPS: $2.08 and $7.30 per share
Result: reported results

Exact text from the filing

the net loss for the three and nine months ended September 30, 2023 was $2.29 million and $7.65 million, or $2.08 and $7.30 per share, respectively

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-085197

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.